Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
«Желудочный экспресс»: оптимизация диагностики и лечения заболеваний пищевода и желудка
«Желудочный экспресс»: оптимизация диагностики и лечения заболеваний пищевода и желудка
Вялов С.С. «Желудочный экспресс»: оптимизация диагностики и лечения заболеваний пищевода и желудка. Справочник поликлинического врача. 2019; 1: 38–45.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Обзор современного подхода к диагностике и лечению болезней пищевода и желудка в общей практике. Анализируются диагностические возможности и спектр заболевания на амбулаторно-поликлиническом этапе. Приводятся диагностические критерии основных заболеваний, даются общие подходы и алгоритмы стартовой диагностики.
Ключевые слова: изжога, рефлюкс, синдром, диспепсия, гастрит, атрофия, эзофагит, пищевод Барретта, хеликобактерная инфекция, Helicobacter pylori, эрадикация, ребамипид, проницаемость.
Key words: heartburn, reflux, syndrome, dyspepsia, gastritis, atrophy, esophagitis, Barrett's esophagus, Helicobacter pylori, eradication, rebamipide, permeability.
Ключевые слова: изжога, рефлюкс, синдром, диспепсия, гастрит, атрофия, эзофагит, пищевод Барретта, хеликобактерная инфекция, Helicobacter pylori, эрадикация, ребамипид, проницаемость.
________________________________________________
Key words: heartburn, reflux, syndrome, dyspepsia, gastritis, atrophy, esophagitis, Barrett's esophagus, Helicobacter pylori, eradication, rebamipide, permeability.
Полный текст
Список литературы
1. Elta GH, Appelman HD, Behler EM et al. A study of the correlation between endoscopic and histological diagnoses in gastroduodenitis. Am J Gastroenterol 1987; 82: 749.
2. Jönsson KA, Gotthard R, Bodemar G, Brodin U. The clinical relevance of endoscopic and histologic inflammation of gastroduodenal mucosa in dyspepsia of unknown origin. Scand J Gastroenterol 1989; 24: 385.
3. Böhmer AC, Schumacher J. Insights into the genetics of gastroesophageal reflux disease (GERD) and GERD-related disorders. Neurogastroenterol Motil 2017; 29 (2).
4. Savarino E, Bredenoord AJ, Fox M et al. Expert consensus document: Advances in the physiological assessment and diagnosis of GERD. Nat Rev Gastroenterol Hepatol 2017; 14 (11): 665–76.
5. Gyawali CP, Kahrilas PJ, Savarino E et al. Modern diagnosis of GERD: the Lyon Consensus. Gut 2018; 67 (7): 1351–62.
6. Вялов С.С. Особенности диагностики и лечения функциональных нарушений желудочно-кишечного тракта. Справочник поликлинического врача. 2012; 8: 54–9. / Vyalov S.S. Osobennosti diagnostiki i lecheniia funktsional'nykh narushenii zheludochno-kishechnogo trakta.Handbook for Practitioners Doctors. 2012; 8: 54–9. [in Russian]
7. Вялов С.С. Что принимать после переедания: ферменты или прокинетики? РМЖ. 2018; 1: 24–9. / Vyalov S.S. Chto prinimat' posle pereedaniia: fermenty ili prokinetiki? RMZh. 2018; 1: 24–9. [in Russian]
8. Лазебник Л.Б., Алексеенко С.А., Лялюкова Е.А. и др. Рекомендации по ведению первичных пациентов с симптомами диспепсии. Экспериментальная и клиническая гастроэнтерология. 2018; 153 (05): 4–18. / Lazebnik L.B., Alekseenko S.A., Lialiukova E.A. i dr. Rekomendatsii po vedeniiu pervichnykh patsientov s simptomami dispepsii. Eksperimental'naia i klinicheskaia gastroenterologiia. 2018; 153 (05): 4–18. [in Russian]
9. Drossman DA, Hasler WL. Rome IV – Functional GI disorders: disorders of Gut-Brain interaction. Gastroenterology 2016; 150 (6): 1262–79.
10. Talley NJ. AGA medical position statement: evaluation of dyspepsia. Gastroenterology 2005; 129: 1753.
11. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001; 96: 689.
12. Вялов С.С. Комплексная терапия рецидивирующих гастродуоденитов. Рациональная фармакотерапия в гастроэнтерологии. Материалы XII конференции. М., 2012; с. 4–5. / Vyalov S.S. Kompleksnaia terapiia retsidiviruiushchikh gastroduodenitov. Ratsional'naia farmakoterapiia v gastroenterologii. Materialy XII konferentsii. M., 2012; s. 4–5. [in Russian]
13. Вялов С.С. Хронический гастрит: клинические варианты и лечение. Consilium Medicum. Гастроэнтерология. 2017; 19 (8): 103–9. / Vyalov S.S. Chronic gastritis: clinical variants and treatment. Consilium Medicum. 2017; 19 (8): 103–9. DOI: 10.26442/2075-1753_19.8.103-109 [in Russian]
14. Вялов С.С., Симаненков В.И. Хронический гастрит: инструкция по применению. Терапевтический архив. 2017; 89 (8): 137–41. / Vyalov S.S., Simanenkov V.I. Khronicheskii gastrit: instruktsiia po primeneniiu. Therapeutic Archive. 2017; 89 (8): 137–41. [in Russian]
15. Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis 2007; 8: 8.
16. Ricci C, Vakil N, Rugge M et al. Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am J Gastroenterol 2004; 99: 1910.
17. Haj-Sheykholeslami A, Rakhshani N, Amirzargar A et al. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. Clin Gastroenterol Hepatol 2008; 6: 174.
18. Вялов С.С. Язвенная болезнь и Маастрихт-4: внедрение в клиническую практику. Эффективная фармакотерапия в гастроэнтерологии. 2012; 6: 16–22. / Vyalov S.S. Iazvennaia bolezn' i Maastrikht-4: vnedrenie v klinicheskuiu praktiku. Effektivnaia farmakoterapiia v gastroenterologii. 2012; 6: 16–22. [in Russian]
19. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6–30.
20. Вялов С.С. Этиология гастритов и восстановление слизистой оболочки верхних отделов ЖКТ. Доктор.ру. 2014; 91 (3): 70–7. / Vialov S.S. Etiologiia gastritov i vosstanovlenie slizistoi obolochki verkhnikh otdelov ZhKT. Doktor.ru. 2014; 91 (3): 70–7. [in Russian]
21. Вялов С.С Восстановление слизистой оболочки желудочно-кишечного тракта или снижение кислотности желудка. Приоритеты в лечении. Эффективная фармакотерапия. 2016; 1. / Vyalov S.S Vosstanovlenie slizistoi obolochki zheludochno-kishechnogo trakta ili snizhenie kislotnosti zheludka. Prioritety v lechenii. Effektivnaia farmakoterapiia. 2016; 1. [in Russian]
22. Zhang S, Qing Q, Bai Y et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci 2013; 58 (7): 1991–2000.
23. Shin WG, Kim SJ, Choi MH. Can rebamipide and proton pump inhibitor combination therapy promote the healing of endoscopic submucosal dissection-induced ulcers? A randomized, prospective, multicenter study. Gastrointest Endosc 2012; 75 (4): 739–47.
24. Fujiwara S, Morita Y, Toyonaga T. A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection. J Gastroenterol 2011; 46 (5): 595–602.
25. Terano A, Arakawa T, Sugiyama T et al. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol 2007; 42 (8): 690–3.
26. Takayama M, Matsui S, Kawasaki M et al. Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers. World J Gastroenterol 2013; 19 (34): 5706–12.
27. Лапина Т.Л., Ивашкин В.Т. Современные подходы к лечению язвенной болезни желудка и двенадцатиперстной кишки. Болезни органов пищеварения. 2001; 3 (1): 10–5. / Lapina T.L., Ivashkin V.T. Sovremennye podkhody k lecheniiu iazvennoi bolezni zheludka i dvenadtsatiperstnoi kishki. Bolezni organov pishchevareniia. 2001; 3 (1): 10–5. [in Russian]
2. Jönsson KA, Gotthard R, Bodemar G, Brodin U. The clinical relevance of endoscopic and histologic inflammation of gastroduodenal mucosa in dyspepsia of unknown origin. Scand J Gastroenterol 1989; 24: 385.
3. Böhmer AC, Schumacher J. Insights into the genetics of gastroesophageal reflux disease (GERD) and GERD-related disorders. Neurogastroenterol Motil 2017; 29 (2).
4. Savarino E, Bredenoord AJ, Fox M et al. Expert consensus document: Advances in the physiological assessment and diagnosis of GERD. Nat Rev Gastroenterol Hepatol 2017; 14 (11): 665–76.
5. Gyawali CP, Kahrilas PJ, Savarino E et al. Modern diagnosis of GERD: the Lyon Consensus. Gut 2018; 67 (7): 1351–62.
6. Vyalov S.S. Osobennosti diagnostiki i lecheniia funktsional'nykh narushenii zheludochno-kishechnogo trakta.Handbook for Practitioners Doctors. 2012; 8: 54–9. [in Russian]
7. Vyalov S.S. Chto prinimat' posle pereedaniia: fermenty ili prokinetiki? RMZh. 2018; 1: 24–9. [in Russian]
8. Lazebnik L.B., Alekseenko S.A., Lialiukova E.A. i dr. Rekomendatsii po vedeniiu pervichnykh patsientov s simptomami dispepsii. Eksperimental'naia i klinicheskaia gastroenterologiia. 2018; 153 (05): 4–18. [in Russian]
9. Drossman DA, Hasler WL. Rome IV – Functional GI disorders: disorders of Gut-Brain interaction. Gastroenterology 2016; 150 (6): 1262–79.
10. Talley NJ. AGA medical position statement: evaluation of dyspepsia. Gastroenterology 2005; 129: 1753.
11. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001; 96: 689.
12. Vyalov S.S. Kompleksnaia terapiia retsidiviruiushchikh gastroduodenitov. Ratsional'naia farmakoterapiia v gastroenterologii. Materialy XII konferentsii. M., 2012; s. 4–5. [in Russian]
13. Vyalov S.S. Chronic gastritis: clinical variants and treatment. Consilium Medicum. 2017; 19 (8): 103–9. DOI: 10.26442/2075-1753_19.8.103-109 [in Russian]
14. Vyalov S.S., Simanenkov V.I. Khronicheskii gastrit: instruktsiia po primeneniiu. Therapeutic Archive. 2017; 89 (8): 137–41. [in Russian]
15. Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis 2007; 8: 8.
16. Ricci C, Vakil N, Rugge M et al. Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am J Gastroenterol 2004; 99: 1910.
17. Haj-Sheykholeslami A, Rakhshani N, Amirzargar A et al. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. Clin Gastroenterol Hepatol 2008; 6: 174.
18. Vyalov S.S. Iazvennaia bolezn' i Maastrikht-4: vnedrenie v klinicheskuiu praktiku. Effektivnaia farmakoterapiia v gastroenterologii. 2012; 6: 16–22. [in Russian]
19. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6–30.
20. Vialov S.S. Etiologiia gastritov i vosstanovlenie slizistoi obolochki verkhnikh otdelov ZhKT. Doktor.ru. 2014; 91 (3): 70–7. [in Russian]
21. Vyalov S.S Vosstanovlenie slizistoi obolochki zheludochno-kishechnogo trakta ili snizhenie kislotnosti zheludka. Prioritety v lechenii. Effektivnaia farmakoterapiia. 2016; 1. [in Russian]
22. Zhang S, Qing Q, Bai Y et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci 2013; 58 (7): 1991–2000.
23. Shin WG, Kim SJ, Choi MH. Can rebamipide and proton pump inhibitor combination therapy promote the healing of endoscopic submucosal dissection-induced ulcers? A randomized, prospective, multicenter study. Gastrointest Endosc 2012; 75 (4): 739–47.
24. Fujiwara S, Morita Y, Toyonaga T. A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection. J Gastroenterol 2011; 46 (5): 595–602.
25. Terano A, Arakawa T, Sugiyama T et al. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol 2007; 42 (8): 690–3.
26. Takayama M, Matsui S, Kawasaki M et al. Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers. World J Gastroenterol 2013; 19 (34): 5706–12.
27. Lapina T.L., Ivashkin V.T. Sovremennye podkhody k lecheniiu iazvennoi bolezni zheludka i dvenadtsatiperstnoi kishki. Bolezni organov pishchevareniia. 2001; 3 (1): 10–5. [in Russian]
2. Jönsson KA, Gotthard R, Bodemar G, Brodin U. The clinical relevance of endoscopic and histologic inflammation of gastroduodenal mucosa in dyspepsia of unknown origin. Scand J Gastroenterol 1989; 24: 385.
3. Böhmer AC, Schumacher J. Insights into the genetics of gastroesophageal reflux disease (GERD) and GERD-related disorders. Neurogastroenterol Motil 2017; 29 (2).
4. Savarino E, Bredenoord AJ, Fox M et al. Expert consensus document: Advances in the physiological assessment and diagnosis of GERD. Nat Rev Gastroenterol Hepatol 2017; 14 (11): 665–76.
5. Gyawali CP, Kahrilas PJ, Savarino E et al. Modern diagnosis of GERD: the Lyon Consensus. Gut 2018; 67 (7): 1351–62.
6. Вялов С.С. Особенности диагностики и лечения функциональных нарушений желудочно-кишечного тракта. Справочник поликлинического врача. 2012; 8: 54–9. / Vyalov S.S. Osobennosti diagnostiki i lecheniia funktsional'nykh narushenii zheludochno-kishechnogo trakta.Handbook for Practitioners Doctors. 2012; 8: 54–9. [in Russian]
7. Вялов С.С. Что принимать после переедания: ферменты или прокинетики? РМЖ. 2018; 1: 24–9. / Vyalov S.S. Chto prinimat' posle pereedaniia: fermenty ili prokinetiki? RMZh. 2018; 1: 24–9. [in Russian]
8. Лазебник Л.Б., Алексеенко С.А., Лялюкова Е.А. и др. Рекомендации по ведению первичных пациентов с симптомами диспепсии. Экспериментальная и клиническая гастроэнтерология. 2018; 153 (05): 4–18. / Lazebnik L.B., Alekseenko S.A., Lialiukova E.A. i dr. Rekomendatsii po vedeniiu pervichnykh patsientov s simptomami dispepsii. Eksperimental'naia i klinicheskaia gastroenterologiia. 2018; 153 (05): 4–18. [in Russian]
9. Drossman DA, Hasler WL. Rome IV – Functional GI disorders: disorders of Gut-Brain interaction. Gastroenterology 2016; 150 (6): 1262–79.
10. Talley NJ. AGA medical position statement: evaluation of dyspepsia. Gastroenterology 2005; 129: 1753.
11. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001; 96: 689.
12. Вялов С.С. Комплексная терапия рецидивирующих гастродуоденитов. Рациональная фармакотерапия в гастроэнтерологии. Материалы XII конференции. М., 2012; с. 4–5. / Vyalov S.S. Kompleksnaia terapiia retsidiviruiushchikh gastroduodenitov. Ratsional'naia farmakoterapiia v gastroenterologii. Materialy XII konferentsii. M., 2012; s. 4–5. [in Russian]
13. Вялов С.С. Хронический гастрит: клинические варианты и лечение. Consilium Medicum. Гастроэнтерология. 2017; 19 (8): 103–9. / Vyalov S.S. Chronic gastritis: clinical variants and treatment. Consilium Medicum. 2017; 19 (8): 103–9. DOI: 10.26442/2075-1753_19.8.103-109 [in Russian]
14. Вялов С.С., Симаненков В.И. Хронический гастрит: инструкция по применению. Терапевтический архив. 2017; 89 (8): 137–41. / Vyalov S.S., Simanenkov V.I. Khronicheskii gastrit: instruktsiia po primeneniiu. Therapeutic Archive. 2017; 89 (8): 137–41. [in Russian]
15. Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis 2007; 8: 8.
16. Ricci C, Vakil N, Rugge M et al. Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am J Gastroenterol 2004; 99: 1910.
17. Haj-Sheykholeslami A, Rakhshani N, Amirzargar A et al. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. Clin Gastroenterol Hepatol 2008; 6: 174.
18. Вялов С.С. Язвенная болезнь и Маастрихт-4: внедрение в клиническую практику. Эффективная фармакотерапия в гастроэнтерологии. 2012; 6: 16–22. / Vyalov S.S. Iazvennaia bolezn' i Maastrikht-4: vnedrenie v klinicheskuiu praktiku. Effektivnaia farmakoterapiia v gastroenterologii. 2012; 6: 16–22. [in Russian]
19. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6–30.
20. Вялов С.С. Этиология гастритов и восстановление слизистой оболочки верхних отделов ЖКТ. Доктор.ру. 2014; 91 (3): 70–7. / Vialov S.S. Etiologiia gastritov i vosstanovlenie slizistoi obolochki verkhnikh otdelov ZhKT. Doktor.ru. 2014; 91 (3): 70–7. [in Russian]
21. Вялов С.С Восстановление слизистой оболочки желудочно-кишечного тракта или снижение кислотности желудка. Приоритеты в лечении. Эффективная фармакотерапия. 2016; 1. / Vyalov S.S Vosstanovlenie slizistoi obolochki zheludochno-kishechnogo trakta ili snizhenie kislotnosti zheludka. Prioritety v lechenii. Effektivnaia farmakoterapiia. 2016; 1. [in Russian]
22. Zhang S, Qing Q, Bai Y et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci 2013; 58 (7): 1991–2000.
23. Shin WG, Kim SJ, Choi MH. Can rebamipide and proton pump inhibitor combination therapy promote the healing of endoscopic submucosal dissection-induced ulcers? A randomized, prospective, multicenter study. Gastrointest Endosc 2012; 75 (4): 739–47.
24. Fujiwara S, Morita Y, Toyonaga T. A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection. J Gastroenterol 2011; 46 (5): 595–602.
25. Terano A, Arakawa T, Sugiyama T et al. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol 2007; 42 (8): 690–3.
26. Takayama M, Matsui S, Kawasaki M et al. Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers. World J Gastroenterol 2013; 19 (34): 5706–12.
27. Лапина Т.Л., Ивашкин В.Т. Современные подходы к лечению язвенной болезни желудка и двенадцатиперстной кишки. Болезни органов пищеварения. 2001; 3 (1): 10–5. / Lapina T.L., Ivashkin V.T. Sovremennye podkhody k lecheniiu iazvennoi bolezni zheludka i dvenadtsatiperstnoi kishki. Bolezni organov pishchevareniia. 2001; 3 (1): 10–5. [in Russian]
________________________________________________
2. Jönsson KA, Gotthard R, Bodemar G, Brodin U. The clinical relevance of endoscopic and histologic inflammation of gastroduodenal mucosa in dyspepsia of unknown origin. Scand J Gastroenterol 1989; 24: 385.
3. Böhmer AC, Schumacher J. Insights into the genetics of gastroesophageal reflux disease (GERD) and GERD-related disorders. Neurogastroenterol Motil 2017; 29 (2).
4. Savarino E, Bredenoord AJ, Fox M et al. Expert consensus document: Advances in the physiological assessment and diagnosis of GERD. Nat Rev Gastroenterol Hepatol 2017; 14 (11): 665–76.
5. Gyawali CP, Kahrilas PJ, Savarino E et al. Modern diagnosis of GERD: the Lyon Consensus. Gut 2018; 67 (7): 1351–62.
6. Vyalov S.S. Osobennosti diagnostiki i lecheniia funktsional'nykh narushenii zheludochno-kishechnogo trakta.Handbook for Practitioners Doctors. 2012; 8: 54–9. [in Russian]
7. Vyalov S.S. Chto prinimat' posle pereedaniia: fermenty ili prokinetiki? RMZh. 2018; 1: 24–9. [in Russian]
8. Lazebnik L.B., Alekseenko S.A., Lialiukova E.A. i dr. Rekomendatsii po vedeniiu pervichnykh patsientov s simptomami dispepsii. Eksperimental'naia i klinicheskaia gastroenterologiia. 2018; 153 (05): 4–18. [in Russian]
9. Drossman DA, Hasler WL. Rome IV – Functional GI disorders: disorders of Gut-Brain interaction. Gastroenterology 2016; 150 (6): 1262–79.
10. Talley NJ. AGA medical position statement: evaluation of dyspepsia. Gastroenterology 2005; 129: 1753.
11. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001; 96: 689.
12. Vyalov S.S. Kompleksnaia terapiia retsidiviruiushchikh gastroduodenitov. Ratsional'naia farmakoterapiia v gastroenterologii. Materialy XII konferentsii. M., 2012; s. 4–5. [in Russian]
13. Vyalov S.S. Chronic gastritis: clinical variants and treatment. Consilium Medicum. 2017; 19 (8): 103–9. DOI: 10.26442/2075-1753_19.8.103-109 [in Russian]
14. Vyalov S.S., Simanenkov V.I. Khronicheskii gastrit: instruktsiia po primeneniiu. Therapeutic Archive. 2017; 89 (8): 137–41. [in Russian]
15. Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis 2007; 8: 8.
16. Ricci C, Vakil N, Rugge M et al. Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am J Gastroenterol 2004; 99: 1910.
17. Haj-Sheykholeslami A, Rakhshani N, Amirzargar A et al. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. Clin Gastroenterol Hepatol 2008; 6: 174.
18. Vyalov S.S. Iazvennaia bolezn' i Maastrikht-4: vnedrenie v klinicheskuiu praktiku. Effektivnaia farmakoterapiia v gastroenterologii. 2012; 6: 16–22. [in Russian]
19. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6–30.
20. Vialov S.S. Etiologiia gastritov i vosstanovlenie slizistoi obolochki verkhnikh otdelov ZhKT. Doktor.ru. 2014; 91 (3): 70–7. [in Russian]
21. Vyalov S.S Vosstanovlenie slizistoi obolochki zheludochno-kishechnogo trakta ili snizhenie kislotnosti zheludka. Prioritety v lechenii. Effektivnaia farmakoterapiia. 2016; 1. [in Russian]
22. Zhang S, Qing Q, Bai Y et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci 2013; 58 (7): 1991–2000.
23. Shin WG, Kim SJ, Choi MH. Can rebamipide and proton pump inhibitor combination therapy promote the healing of endoscopic submucosal dissection-induced ulcers? A randomized, prospective, multicenter study. Gastrointest Endosc 2012; 75 (4): 739–47.
24. Fujiwara S, Morita Y, Toyonaga T. A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection. J Gastroenterol 2011; 46 (5): 595–602.
25. Terano A, Arakawa T, Sugiyama T et al. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol 2007; 42 (8): 690–3.
26. Takayama M, Matsui S, Kawasaki M et al. Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers. World J Gastroenterol 2013; 19 (34): 5706–12.
27. Lapina T.L., Ivashkin V.T. Sovremennye podkhody k lecheniiu iazvennoi bolezni zheludka i dvenadtsatiperstnoi kishki. Bolezni organov pishchevareniia. 2001; 3 (1): 10–5. [in Russian]
Авторы
С.С.Вялов
ФГАОУ ВО «Российский университет дружбы народов». 117198, Россия, Москва, ул. Миклухо-Маклая, д. 6
www.vyalov.com
People’s Friendship University of Russia. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaya, d. 6
www.vyalov.com
ФГАОУ ВО «Российский университет дружбы народов». 117198, Россия, Москва, ул. Миклухо-Маклая, д. 6
www.vyalov.com
________________________________________________
People’s Friendship University of Russia. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaya, d. 6
www.vyalov.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.